At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
[68Ga]Ga-OncoCAIXdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
In Brief
A Phase 1 clinical trial evaluating [68Ga]Ga-OncoCAIX for Clear Cell Renal Cell Carcinoma (ccRCC). Completed, enrolled 20 participants across 3 sites.
Detailed Summary
Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear Cell Renal Cell Carcinoma (ccRCC)
CountriesItaly
Collaborators--
Timeline
Phase 1CompletedFinished
2026
First PostedFeb 2025
Enrollment StartApr 2025
Primary CompletionNov 2025
TodayJul 2026
First PostedFeb 21, 2025
Enrollment StartApr 16, 2025
Primary CompletionNov 28, 2025
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 1.4 years ago
Interventions
[68Ga]Ga-OncoCAIXdrug
Single intravenous bolus administration.